Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Prospective, Randomized, Multicenter, Double-blind, Active-control, Parallel-group Study to Determine the Safety of and to Select a Treatment Regimen of CC-4047 (Pomalidomide) Either as Single-agent or in Combination With Prednisone to Study Further in Subjects With Myelofibrosis With Myeloid Metaplasia

NCT00463385 is registered in ClinicalTrials.gov with Celgene as lead sponsor.

NCT NCT00463385
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00463385 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Prospective, Randomized, Multicenter, Double-blind, Active-control, Parallel-group Study to Determine the Safety of and to Select a Treatment Regimen of CC-4047 (Pomalidomide) Either as Single-agent or in Combination With Prednisone to Study Further in Subjects With Myelofibrosis With Myeloid Metaplasia
Lead sponsor
Celgene
Phase
Phase 2
Overall status
Completed
Start date
April 1, 2007
Completion date
December 31, 2013
Enrollment
88 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

myelofibrosis, myelofibrosis with myeloid metaplasia, myeloid metaplasia